← ANALYST RATINGS · TIPRANKS
Apnimed, Inc. (APMD): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $50.50, the highest $60.00, the lowest $41.00. The average is +184.3% from the last price of $17.76.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $41.00 | Buy | +130.9% | Reiterated | 12.10.26on TipRanks 08:45 | +0.7%next day −4.3% | ↗ |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $50.00 | Buy | +181.5% | Reiterated | 09.09.26on TipRanks 09:09 | −2.0%next day −4.0% · 5 days −2.4% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $60.00 | Buy | +237.8% | Initiated | 25.08.26on TipRanks Aug 26 08:20 | +6.5%next day +8.1% · 5 days −1.4% | ↗ |
| Umer Raffat★★★★★★★★★★#2336 · hits 50% · avg +9.4% | Evercore ISI | — | Buy | — | Initiated | 25.08.26on TipRanks 06:30 | +6.5%next day +8.1% · 5 days −1.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Apnimed, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $50.33 at a price of $21.91 (+129.7%); now: $50.33 at $17.76 (+183.4%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 1 | 2 |
| Buy | 0 | 0 | 0 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Apnimed, Inc.
- CEO: Kevin R. Lind
- Employees: 65
- 39 John F. Kennedy Street, Cambridge, MA, 02138, US
- apnimed.com
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 74 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗